A61P 19 - Drugs for skeletal disorders

Patents for A61P 19 - Drugs for skeletal disorders (81,981)
10/2001
10/24/2001	CN1318402A Medicine for traumatic fracture pain
10/24/2001	CN1318391A Gulingdan for treating osteological disease and its preparation
10/24/2001	CN1318371A New use of flavone
10/24/2001	CN1073557C Vitamin-D amide derivatives
10/23/2001	US6307092 Potent ocular hypotensives and are particularly suited for the management of glaucoma.
10/23/2001	US6307089 Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
10/23/2001	US6307061 Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
10/23/2001	US6307044 Process for the preparation of macrocyclic metalloprotease inhibitors
10/23/2001	US6307021 Polypeptide; for use in the treatment of defects associated with amplified or decreased apoptosis
10/23/2001	US6306911 Enzyme inhibitors
10/23/2001	US6306887 Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
10/23/2001	US6306886 Solid polymorph anticoagulants
10/23/2001	US6306881 Anti-inflammatory agents
10/23/2001	US6306879 Isotonic glucose solution
10/23/2001	US6306875 Growth-hormone secretagogues
10/23/2001	US6306874 Enzyme inhibitors such as angiogenesis, cancer, tumor growth, atherosclerosis, age related macular degeneration, diabetic retinopathy, inflammatory diseases, and the like in mammals.
10/23/2001	US6306873 Substituted β-thiocarboxylic acids
10/23/2001	US6306863 Pyrrolo[3,4-d]pyrimidinone derivatives and their use as medicaments
10/23/2001	US6306844 Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
10/23/2001	US6306822 Phosphopeptides and methods of treating bone diseases
10/23/2001	US6306820 Combination therapy using a TNF binding protein for treating TNF-mediated diseases
10/23/2001	CA2223817C Compositions for the treatment of rheumatoid-based arthritic diseases
10/23/2001	CA2107150C Chromenic derivatives having a triene lateral chain, process for the preparation thereof and pharmaceutical compositions containing them
10/18/2001	WO2001077327A1 THE HIGH BONE MASS GENE OF 11q13.3
10/18/2001	WO2001077174A2 Human transporters and ion channels
10/18/2001	WO2001077149A2 Regulation of human cyslt2-like gpcr protein
10/18/2001	WO2001077146A2 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	WO2001077145A2 Integrin binding peptide derivatives
10/18/2001	WO2001077139A1 8ss-HYDROCARBYL-SUBSTITUTED ESTRATRIENES FOR USE AS SELECTIVE ESTROGENS
10/18/2001	WO2001077138A1 8β-SUBSTITUTED-11β-PENTYL- AND 11β-HEXYL-ESTRA-1,3,5(10)-TRIENE DERIVATIVES
10/18/2001	WO2001077137A1 Albumin fusion proteins
10/18/2001	WO2001077101A1 Chemical compounds
10/18/2001	WO2001077100A2 Benzoamide piperidine compounds as substance p antagonists
10/18/2001	WO2001077093A1 Estrogen agonist/antagonist metabolites
10/18/2001	WO2001077092A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/18/2001	WO2001077087A1 Novel compounds
10/18/2001	WO2001077085A1 Quinazoline compounds
10/18/2001	WO2001077075A2 Inhibitors of inflammation and reperfusion injury
10/18/2001	WO2001077073A1 Cathepsin cysteine protease inhibitors
10/18/2001	WO2001077069A1 Naphthamide neurokinin antagonists for use as medicaments
10/18/2001	WO2001077057A2 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001077055A2 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	WO2001076654A1 Methods and compositions for treating intervertebral disc degeneration
10/18/2001	WO2001076649A1 An injectable bone mineral substitute material
10/18/2001	WO2001076606A2 Use of uric acid or precursors thereof as a treatment for cancer, aids and the like
10/18/2001	WO2001076589A1 Dermatological use and a dermatological preparation
10/18/2001	WO2001076584A2 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	WO2001076578A2 Treatment of icu-associated hypocalcemia with vitamin d compounds
10/18/2001	WO2001076577A2 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	WO2001076572A2 Use of compatible solutes as substances having free radical scavenging properties
10/18/2001	WO2001076530A2 Il-8 receptor antagonists
10/18/2001	WO2001039724A3 Phosphonate compounds
10/18/2001	WO2001026737A3 Treatment of excessive bone or cartilage loss with an activator of ror alpha and assay for identifying such activator
10/18/2001	WO2001026640A3 Treatment of osteoporosis
10/18/2001	WO2001025435A3 In vivo treatment of joint disease using interleukin-1 receptor antagonists
10/18/2001	WO2001022090A9 Method for identifying compounds useful in the therapy of bone disorders
10/18/2001	WO2001015715A3 Composition for maintenance of bone or dental health or treatment of bone or dental disorders
10/18/2001	WO2000047130A9 Injectable collagen-based system for delivery of cells or therapeutic agents
10/18/2001	WO2000035436A3 Treatment of arthritis with mek inhibitors
10/18/2001	US20010031882 Lipoxin compounds and their use in treating cell proliferative disorders
10/18/2001	US20010031878 Novel processes for making- and a new crystalline form of- leflunomide
10/18/2001	US20010031788 Anticancer agents, osteoporosis, arteriosclerosis, restnosis,vision defects
10/18/2001	US20010031777 Heterocyclic compounds and their therapeutic use
10/18/2001	US20010031766 Prostaglandin receptor ligands
10/18/2001	US20010031757 Administering compounds such as 3-(2-phenylethylamino)-6-methyl-1-(2-amino-6-methyl-5-methylene -carboxamidomethylpyridi nyl)-2-pyrazinone, N'-((1-(Aminoiminomethyl)4-piperidinyl) methyl)-N-(3,3- diphenylpropionyl)-L-proline amide
10/18/2001	US20010031725 Polysaccharides
10/18/2001	US20010031274 Biodegradable polymer
10/18/2001	US20010031261 Use of genetically engineered antibodies to treat multiple myeloma
10/18/2001	US20010031260 Administering tumor necrosis factor antagonist; rheumatic diseases, skin disorders
10/18/2001	DE10019167A1 New 8 beta-substituted 11 beta-(pentyl or hexyl)-estra-1,3,5(10)-triene derivatives, are ovary-selective estrogen receptor ligands useful e.g. as female or male contraceptives or for treating ovarian carcinoma
10/18/2001	DE10016559A1 System für den Transport von Aktivstoffen in einem biologischen System System for transporting active substances in a biological system
10/18/2001	DE10013782A1 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln 4-fluoroalkyl-2H-benzopyrans with antiestrogenic action, processes for their preparation, pharmaceutical compositions containing them and their use for the preparation of medicaments
10/18/2001	CA2405912A1 Albumin fusion proteins
10/18/2001	CA2405476A1 Compounds and methods for modulating endothelial cell adhesion
10/18/2001	CA2405425A1 Dermatological preparations containing thyronine derivatives and uses thereof
10/18/2001	CA2405411A1 Use of breakers of advanced glycation endproducts for treating deleterious effects of aging and debilitating diseases
10/18/2001	CA2405360A1 Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
10/18/2001	CA2405152A1 Treatment of icu-associated hypocalcemia with vitamin d compounds
10/18/2001	CA2405089A1 Benzoamide piperidine containing compounds and related compounds
10/18/2001	CA2405070A1 Estrogen agonist/antagonist metabolites
10/18/2001	CA2404630A1 Cathepsin cysteine protease inhibitors
10/18/2001	CA2404229A1 Human transporters and ion channels
10/18/2001	CA2403365A1 Quinazoline compounds
10/18/2001	CA2403263A1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403144A1 Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
10/18/2001	CA2403012A1 Chemical compounds
10/18/2001	CA2402410A1 The high bone mass gene of 11q13.3
10/18/2001	CA2372352A1 Sulfonamide derivative as a matrix metalloproteinase inhibitor
10/17/2001	EP1145001A2 (in vitro) model for gastrointestinal inflammation
10/17/2001	EP1144997A2 Methods and compounds for modulating nuclear receptor activity
10/17/2001	EP1144686A2 Genetic predisposition to abnormal calcification conditions
10/17/2001	EP1144682A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
10/17/2001	EP1144673A1 Methods of screening protease inhibitors, of inducing mice susceptible to hiv protease inhibitor-induced dyslipidemia, and genes associated therewith
10/17/2001	EP1144648A1 Cyclic nucleotide-associated proteins
10/17/2001	EP1144628A2 Human vanilloid receptor gene
10/17/2001	EP1144614A2 33 human secreted proteins
10/17/2001	EP1144605A2 Dimethylarginine dimethylaminohydrolases
10/17/2001	EP1144598A2 Human homologues of proteins regulated by circadian rhythms
10/17/2001	EP1144459A2 Cross-linked hyaluronic acids and medical uses thereof
10/17/2001	EP1144454A2 Modified peptides as therapeutic agents

1 ... 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 ... 820